Jaguar health reports third quarter 2024 financial results

The combined net q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net q2 2024 revenue of $2.7 million and 11% versus net q3 2023 revenue of $2.8 million jaguar reported significant results in breast cancer patients in its phase 3 ontarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on december 11, 2024 at the san antonio breast cancer symposium (sabcs) jaguar initiated commercial launch in october 2024 for gelclair ®, the company's third prescription product, in alignment with jaguar's focus on cancer supportive care jaguar is initiating two phase 2 trials in q4, 2024 and supporting multiple investigator-initiated proof-of-concept studies ("iit") of crofelemer for the rare and orphan disease indications of microvillus inclusion disease (mvid) and short bowel syndrome (sbs) with intestinal failure in the us, eu, and middle east/north africa (mena) regions; results of iits expected by the end of 2024 and throughout 2025 reminder: jaguar to host investor webcast wednesday, november 13th at 8:30 a.m. eastern regarding q3 2024 financials and company updates; click here to register for webcast san francisco, ca / accesswire / november 13, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported its consolidated third-quarter 2024 financial results and provided company updates.
JAGX Ratings Summary
JAGX Quant Ranking